NASDAQ:STAB Statera Biopharma (STAB) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 09/23/2026 03:23 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsNews and Trends About Statera Biopharma Stock (NASDAQ:STAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Statera Biopharma alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.00▼$0.03Volume2,050 shsAverage Volume10,508 shsMarket Capitalization$1.33 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Statera Biopharma, Inc. was a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. Its research programs targeted conditions involving abnormal or excessive immune responses, including autoimmune and inflammatory diseases, cancer, and certain infectious diseases. The company’s development approach centered on proprietary immune-modulating drug candidates intended to regulate immune-cell activity rather than broadly suppressing the immune system. Statera’s programs remained in the research and clinical-development stages, and the company did not have a broad portfolio of commercially marketed products. Statera Biopharma was formerly known as Cytocom, Inc. and adopted the Statera name as part of its corporate development. Publicly available information primarily describes the company’s scientific platform and early-stage pipeline; reliable current information regarding its operations, leadership, geographic reach, and commercial activities is limited.AI Generated. May Contain Errors. Read More Receive STAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Statera Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STAB Stock News HeadlinesStatera Biopharma Inc. (STAB)May 23, 2026 | nasdaq.comBNP Paribas Primary New Issues: No STAB Notice - HOMEVIMay 14, 2026 | globenewswire.comBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.September 24 at 1:00 AM | Decentralized Masters (Ad)BNP Paribas Primary New Issues: Post-STAB Notice - No Stab NEW IMMO HOLDINGApril 17, 2026 | globenewswire.comAZELIS - BNP Paribas Primary New Issues: NO STAB NoticeMarch 5, 2026 | globenewswire.comBNP Paribas Primary New Issues: POST-STAB Notice: No Stab - Gruppo San Donato S.P.A.October 27, 2025 | globenewswire.comStatera Biopharma Inc.October 10, 2025 | barrons.comTivic Health receives two investigational new drug applications from StateraAugust 20, 2025 | msn.comSee More Headlines STAB Stock Analysis - Frequently Asked Questions How have STAB shares performed this year? Statera Biopharma's stock was trading at $0.0003 on January 1st, 2026. Since then, STAB stock has decreased by 66.7% and is now trading at $0.0001. How do I buy shares of Statera Biopharma? Shares of STAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Statera Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Statera Biopharma investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Today9/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:STAB CIK1318641 Webwww.staterabiopharma.com Phone(888) 613-8802Fax716-849-6820Employees46Year Founded2003Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares13,340,000Free FloatN/AMarket Cap$1.33 thousand OptionableNot Optionable Beta0.10 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:STAB) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Statera Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Statera Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
